메뉴 건너뛰기




Volumn 95, Issue 42, 2016, Pages

Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials

Author keywords

Meta analysis; Nonalcoholic steatohepatitis; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHOLESTEROL; INSULIN; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL;

EID: 84995550141     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004947     Document Type: Article
Times cited : (45)

References (41)
  • 1
    • 33750606061 scopus 로고    scopus 로고
    • Long-term follow-up of patients with NAFLD and elevated liver enzymes
    • Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.
    • (2006) Hepatology , vol.44 , pp. 865-873
    • Ekstedt, M.1    Franzen, L.E.2    Mathiesen, U.L.3
  • 2
    • 79959573040 scopus 로고    scopus 로고
    • Endpoints and clinical trial design for nonalcoholic steatohepatitis
    • Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344-53.
    • (2011) Hepatology , vol.54 , pp. 344-353
    • Sanyal, A.J.1    Brunt, E.M.2    Kleiner, D.E.3
  • 4
    • 84861543083 scopus 로고    scopus 로고
    • The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
    • Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23.
    • (2012) Hepatology , vol.55 , pp. 2005-2023
    • Chalasani, N.1    Younossi, Z.2    Lavine, J.E.3
  • 5
    • 84877900838 scopus 로고    scopus 로고
    • Gastrointestinal complications of obesity: Non-alcoholic fatty liver disease (NAFLD) and its sequelae
    • Karlas T, Wiegand J, Berg T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab 2013;27:195-208.
    • (2013) Best Pract Res Clin Endocrinol Metab , vol.27 , pp. 195-208
    • Karlas, T.1    Wiegand, J.2    Berg, T.3
  • 6
    • 84863989690 scopus 로고    scopus 로고
    • Review article: Non-alcoholic fatty liver disease and osteoporosis: Clinical and molecular crosstalk
    • Yilmaz Y. Review article: non-alcoholic fatty liver disease and osteoporosis: clinical and molecular crosstalk. Aliment Pharmacol Ther 2012;36:345-52.
    • (2012) Aliment Pharmacol Ther , vol.36 , pp. 345-352
    • Yilmaz, Y.1
  • 7
    • 77955507529 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease: The hepatic consequence of obesity and the metabolic syndrome
    • Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010;69: 211-20.
    • (2010) Proc Nutr Soc , vol.69 , pp. 211-220
    • Moore, J.B.1
  • 9
    • 77952529040 scopus 로고    scopus 로고
    • A position statement on NAFLD/NASH based on the EASL 2009 special conference
    • Ratziu V, Bellentani S, Cortez-Pinto H, Day C,Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-84.
    • (2010) J Hepatol , vol.53 , pp. 372-384
    • Ratziu, V.1    Bellentani, S.2    Cortez-Pinto, H.3    Day Cmarchesini, G.4
  • 10
    • 12144259379 scopus 로고    scopus 로고
    • Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population
    • Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-8.
    • (2005) Am J Physiol Endocrinol Metab , vol.288 , pp. E462-E468
    • Szczepaniak, L.S.1    Nurenberg, P.2    Leonard, D.3
  • 11
    • 10644220306 scopus 로고    scopus 로고
    • Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
    • Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
    • (2004) Hepatology , vol.40 , pp. 1387-1395
    • Browning, J.D.1    Szczepaniak, L.S.2    Dobbins, R.3
  • 13
    • 34250332701 scopus 로고    scopus 로고
    • What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
    • Fan JG, Saibara T, Chitturi S, et al. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol 2007;22:794-800.
    • (2007) J Gastroenterol Hepatol , vol.22 , pp. 794-800
    • Fan, J.G.1    Saibara, T.2    Chitturi, S.3
  • 14
    • 19944394555 scopus 로고    scopus 로고
    • Second World Congress on the Insulin Resistance Syndrome: Insulin resistance syndrome and nonalcoholic fatty liver disease
    • Bloomgarden ZT. Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care 2005;28:1518-23.
    • (2005) Diabetes Care , vol.28 , pp. 1518-1523
    • Bloomgarden, Z.T.1
  • 15
    • 0034831067 scopus 로고    scopus 로고
    • Nonalcoholic steatohepatitis
    • Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001;121: 710-23.
    • (2001) Gastroenterology , vol.121 , pp. 710-723
    • Reid, A.E.1
  • 16
    • 84865545850 scopus 로고    scopus 로고
    • Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis
    • Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012;56:943-51.
    • (2012) Hepatology , vol.56 , pp. 943-951
    • Loomba, R.1    Abraham, M.2    Unalp, A.3
  • 17
    • 0037382786 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver, steatohepatitis,and themetabolic syndrome
    • Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis,and themetabolic syndrome.Hepatology2003;37:917-23.
    • (2003) Hepatology , vol.37 , pp. 917-923
    • Marchesini, G.1    Bugianesi, E.2    Forlani, G.3
  • 18
    • 53549112749 scopus 로고    scopus 로고
    • Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: Causal effect or epiphenomenon?
    • Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008;51:1947-53.
    • (2008) Diabetologia , vol.51 , pp. 1947-1953
    • Targher, G.1    Marra, F.2    Marchesini, G.3
  • 19
    • 0037129380 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver disease
    • Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346: 1221-31.
    • (2002) N Engl J Med , vol.346 , pp. 1221-1231
    • Angulo, P.1
  • 20
    • 0141532275 scopus 로고    scopus 로고
    • Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone
    • Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17.
    • (2003) Hepatology , vol.38 , pp. 1008-1017
    • Neuschwander-Tetri, B.A.1    Brunt, E.M.2    Wehmeier, K.R.3    Oliver, D.4    Bacon, B.R.5
  • 21
    • 1442355447 scopus 로고    scopus 로고
    • A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
    • Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39: 188-96.
    • (2004) Hepatology , vol.39 , pp. 188-196
    • Promrat, K.1    Lutchman, G.2    Uwaifo, G.I.3
  • 23
    • 33751545838 scopus 로고    scopus 로고
    • A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
    • Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl JMed 2006;355:2297-307.
    • (2006) N Engl JMed , vol.355 , pp. 2297-2307
    • Belfort, R.1    Harrison, S.A.2    Brown, K.3
  • 24
    • 45549091794 scopus 로고    scopus 로고
    • Clinical trial: Insulinsensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis
    • Idilman R, Mizrak D, Corapcioglu D, et al. Clinical trial: insulinsensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008;28:200-8.
    • (2008) Aliment Pharmacol Ther , vol.28 , pp. 200-208
    • Idilman, R.1    Mizrak, D.2    Corapcioglu, D.3
  • 25
    • 80055042241 scopus 로고    scopus 로고
    • The role of thiazolidinediones in non-alcoholic steatohepatitis: A systematic review and meta analysis
    • Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic steatohepatitis: a systematic review and meta analysis. J Hepatol 2011;55:1383-90.
    • (2011) J Hepatol , vol.55 , pp. 1383-1390
    • Mahady, S.E.1    Webster, A.C.2    Walker, S.3    Sanyal, A.4    George, J.5
  • 27
    • 68549101842 scopus 로고    scopus 로고
    • The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration
    • Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339: b2700.
    • (2009) BMJ , vol.339 , pp. b2700
    • Liberati, A.1    Altman, D.G.2    Tetzlaff, J.3
  • 28
    • 77951874018 scopus 로고    scopus 로고
    • Pioglitazone, Vitamin E, or placebo for nonalcoholic steatohepatitis
    • Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362: 1675-85.
    • (2010) N Engl J Med , vol.362 , pp. 1675-1685
    • Sanyal, A.J.1    Chalasani, N.2    Kowdley, K.V.3
  • 29
    • 46349088361 scopus 로고    scopus 로고
    • Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial
    • Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135:100-10.
    • (2008) Gastroenterology , vol.135 , pp. 100-110
    • Ratziu, V.1    Giral, P.2    Jacqueminet, S.3
  • 30
    • 53049101877 scopus 로고    scopus 로고
    • Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
    • Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-84.
    • (2008) Gastroenterology , vol.135 , pp. 1176-1184
    • Aithal, G.P.1    Thomas, J.A.2    Kaye, P.V.3
  • 31
    • 34548306770 scopus 로고    scopus 로고
    • The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis
    • Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;46:424-9.
    • (2007) Hepatology , vol.46 , pp. 424-429
    • Lutchman, G.1    Modi, A.2    Kleiner, D.E.3
  • 32
    • 34249745682 scopus 로고    scopus 로고
    • Medical treatment of nonalcoholic steatohepatitis
    • Kadayifci A, Merriman RB, Bass NM. Medical treatment of nonalcoholic steatohepatitis. Clin Liver Dis 2007;11:119-40.
    • (2007) Clin Liver Dis , vol.11 , pp. 119-140
    • Kadayifci, A.1    Merriman, R.B.2    Bass, N.M.3
  • 33
    • 83555164835 scopus 로고    scopus 로고
    • Meta-analysis: Pioglitazone improves liver histology and fibrosis in patients with nonalcoholic steatohepatitis
    • Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2012;35:66-75.
    • (2012) Aliment Pharmacol Ther , vol.35 , pp. 66-75
    • Boettcher, E.1    Csako, G.2    Pucino, F.3    Wesley, R.4    Loomba, R.5
  • 34
    • 84945185644 scopus 로고    scopus 로고
    • Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis
    • Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology 2015;62:1417-32.
    • (2015) Hepatology , vol.62 , pp. 1417-1432
    • Singh, S.1    Khera, R.2    Allen, A.M.3    Murad, M.H.4    Loomba, R.5
  • 35
    • 79960109765 scopus 로고    scopus 로고
    • Pathophysiology of non-alcoholic steatohepatitis and basis for treatment
    • Pinzani M. Pathophysiology of non-alcoholic steatohepatitis and basis for treatment. Dig Dis 2011;29:243-8.
    • (2011) Dig Dis , vol.29 , pp. 243-248
    • Pinzani, M.1
  • 36
    • 77952580372 scopus 로고    scopus 로고
    • Metabolic factors and nonalcoholic fatty liver disease as co-factors in other liver diseases
    • Powell EE, Jonsson JR, Clouston AD. Metabolic factors and nonalcoholic fatty liver disease as co-factors in other liver diseases. Dig Dis 2010;28:186-91.
    • (2010) Dig Dis , vol.28 , pp. 186-191
    • Powell, E.E.1    Jonsson, J.R.2    Clouston, A.D.3
  • 37
    • 30944455145 scopus 로고    scopus 로고
    • Insulin resistance: A metabolic pathway to chronic liver disease
    • Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42: 987-1000.
    • (2005) Hepatology , vol.42 , pp. 987-1000
    • Bugianesi, E.1    McCullough, A.J.2    Marchesini, G.3
  • 38
    • 0035671770 scopus 로고    scopus 로고
    • Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients
    • Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001;44:2210.
    • (2001) Diabetologia , vol.44 , pp. 2210
    • Miyazaki, Y.1    Glass, L.2    Triplitt, C.3
  • 39
    • 0034833667 scopus 로고    scopus 로고
    • Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
    • Miyazaki Y, Mahankali A, MatsudaM, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710.
    • (2001) Diabetes Care , vol.24 , pp. 710
    • Miyazaki, Y.1    Mahankali, A.2    Matsuda, M.3
  • 40
    • 0034735992 scopus 로고    scopus 로고
    • Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone
    • Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278:704.
    • (2000) Biochem Biophys Res Commun , vol.278 , pp. 704
    • Sakamoto, J.1    Kimura, H.2    Moriyama, S.3
  • 41
    • 0036481709 scopus 로고    scopus 로고
    • Synthetic peroxisome proliferatoractivated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients
    • Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferatoractivated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25: 376-80.
    • (2002) Diabetes Care , vol.25 , pp. 376-380
    • Yang, W.S.1    Jeng, C.Y.2    Wu, T.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.